Curated News
By: NewsRamp Editorial Staff
September 04, 2024
Cingulate's Breakthrough Technology Revolutionizes Drug Delivery
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Investors in Cingulate (NASDAQ: CING) may gain an edge with the company's innovative Precision Timed Release™ (PTR™) technology.
- Cingulate's PTR™ technology allows a single pill to contain multiple doses of a drug, providing relief for people with chronic conditions.
- Cingulate's drug technology aims to make life easier for those with chronic conditions, reducing the burden of taking multiple pills.
- Cingulate's Precision Timed Release™ (PTR™) technology is a game-changer in drug delivery, offering hope for those with chronic conditions.
Impact - Why it Matters
This news matters because Cingulate's innovative drug delivery technology has the potential to significantly improve the lives of individuals with chronic conditions by reducing pill burden and providing relief. It also highlights the company's commitment to addressing underserved medical needs.
Summary
Dr. Ann Childress and Shane Schaffer, Chairman & CEO of Cingulate (NASDAQ: CING), were recently guests on Benzinga’s All Access. Cingulate is a biotechnology company developing drugs for a range of underserved conditions. The company has developed a proprietary technology called Precision Timed Release™ (PTR™), allowing a single pill to contain multiple doses of a drug, relieving the pill burden many people with chronic conditions suffer. Cingulate plans to submit a New Drug Application within a year.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Cingulate's Breakthrough Technology Revolutionizes Drug Delivery
